Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00006478 2023-09-18

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

Phase 2 Terminated

19 enrolled 4 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT00004197 2023-09-07

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05794659 2023-07-20

Cornerstone4

Phase 2 Not yet recruiting

98 enrolled

Gynecologic

Advanced Ovarian Cancer

NCT00071981 2023-06-28

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Phase 2 Completed

175 enrolled 12 charts

Dermatologic

Melanoma

NCT00005962 2023-06-22

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT00014508 2023-06-22

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 2 Completed

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00005780 2023-01-31

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Phase 2 Completed

26 enrolled 18 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT02593123 2023-01-23

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Phase 2 Completed

31 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Phase 2 Active not recruiting

280 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2 Terminated

120 enrolled 12 charts

Gynecologic

Ovarian Neoplasms

NCT02641782 2022-11-04

NB2013-HR

Phase 2 Terminated

3 enrolled

CNS

Neuroblastoma

Clinical Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Therapy for Children With Advanced Stage Neuroblastoma

GM-CSF With Post-Transplant Cyclophosphamide

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Metastatic Solid Cancer Clinical Trial

Conerstone3

Cornerstone001

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

I-ATTAC

Vaccine Therapy in Treating Patients With Multiple Myeloma

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

NIPU

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

HER3+

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

LUNGVAC

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

SALIENT

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Cornerstone4

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Sargramostim (GM-CSF) + PD-1

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NB2013-HR